View Future GrowthAcarix 過去の業績過去 基準チェック /06Acarixの収益は年間平均-1.8%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間15.3% 13.5%割合で 増加しています。主要情報-1.78%収益成長率39.92%EPS成長率Medical Equipment 業界の成長8.90%収益成長率13.49%株主資本利益率-115.72%ネット・マージン-530.83%次回の業績アップデート13 Aug 2026最近の業績更新お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025お知らせ • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024お知らせ • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023お知らせ • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024お知らせ • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023すべての更新を表示Recent updatesお知らせ • Feb 13Acarix AB (publ), Annual General Meeting, May 13, 2026Acarix AB (publ), Annual General Meeting, May 13, 2026.お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027お知らせ • Jun 26Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®? System in U.S. Emergency DepartmentsAcarix announced the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®? System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor®? system with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings-estimated between $7.3 million and $15.3 million per 10,000 patients-without compromising patient safety. The CADScor®? System are FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care.お知らせ • May 14Acarix AB (Publ) Approves Election of Jan Poulsen as Director and Chair of the BoardAcarix AB (publ) announced that at its AGM held on 13 May 2025, the shareholders approved election of Jan Poulsen as new director. Jan Poulsen was elected as chair of the board.お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025お知らせ • Nov 12Acarix AB (publ), Annual General Meeting, May 15, 2025Acarix AB (publ), Annual General Meeting, May 15, 2025. Location: stockholm Swedenお知らせ • Aug 13Acarix Expands Within US Wellness Exam MarketAcarix announced expanded use of the CADScor System within wellness exams as part of self-insured companies' health plans. As healthcare costs continue to rise, the CADScor System has now been proven to be an easy and quick strategy to risk stratify patients for significant coronary artery disease. The US employer self-insured market is rapidly expanding to include approximately 60 million Americans. In a self-funded insurance plan, companies bear the direct financial responsibility for their employee's healthcare costs and are acutely aware of the impact that serious health events, such as heart attacks, can have on their bottom line. Acarix has expanded its presence in the self-insured healthcare market, focusing on providing solutions for wellness exams. The first strategic account was signed with Delaware Resource Group, which successfully assessed its employees and families with the CADScor System.お知らせ • Jul 05Acarix AB (publ) announced that it expects to receive SEK 21 million in fundingAcarix AB (publ) announced a private placement to issue 60,000,000 common shares at an issue price of SEK 0.35 per share for the gross proceeds of SEK 21,000,000 on July 3, 2024.お知らせ • Jun 13Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation StudyAcarix announced the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.お知らせ • May 29Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024Acarix AB (publ) announced appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix. Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik Inc., St. Jude Medical, Guidant Corp. (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes. Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships.お知らせ • May 15Acarix AB (publ) Approves Board ElectionsAcarix AB (publ) at its AGM held on May 14, 2024 approved election of Ken Nelson and Dr. Tony Das as new directors.お知らせ • Apr 11Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation StudyAcarix AB announced the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Second Quarter 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States.お知らせ • Feb 15Acarix Appoints New Members to the Advisory BoardAcarix announced the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments. Ken Nelson brings over two decades of experience in the digital health, medical device, and remote patient monitoring industries. As a partner in the Medtech Advantage Fund and Chairman of the Board for CardiaCare, Mr. Nelson has played pivotal roles in numerous disruptive cardiac digital health and MedTech startups worldwide. His track record includes leadership positions in top market share players such as BioTelemetry, iRhythm, and Bardy Diagnostics. Dr. Saumil R. Oza, MD, is an electrophysiologist practicing in Jacksonville, FL, with over 15 years of experience and numerous publications. Renowned as a national expert in cardiology, Dr. Oza serves on advisory boards for established companies like Boston Scientific, Johnson and Johnson, GE, and Novo Nordisk, as well as biotech startups. His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market. Dave Braun, a strategic, customer-driven entrepreneur with over four decades of leadership experience, joins Acarix as an advisor. His extensive background in strategic business planning, mergers and acquisitions, banking and investor relations, organization development, and team building will bring a fresh perspective to operational strategies. Adding these three advisors emphasizes Acarix's commitment to driving innovation in cardiac health while expanding its reach in the United States. The new advisory board members will enhance efforts to develop solutions that improve patient outcomes and advance the standard of care in cardiac diagnostics.お知らせ • Feb 02Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Security Name: Shares Security Type: Common Stock Securities Offered: 181,005,581 Price\Range: SEK 0.186お知らせ • Feb 01Acarix AB (publ) Announces CEO ChangesThe Board of Acarix AB (publ) announced the appointment of Aamir Mahmood as new CEO with immediate effect, starting February 1, 2024. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024. Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO). Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. Aamir Mahmood assumed the CEO position on February 1, 2024.お知らせ • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024お知らせ • Nov 24Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare NetworkAcarix AB (publ) announced an advancement in the utilization of its CADScor System within the Veterans Administration (VA) Healthcare network. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system. The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test. In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System.お知らせ • Oct 19Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 90,573,602 Price\Range: SEK 0.6 Transaction Features: Rights Offeringお知らせ • Aug 29Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical AdvisorAcarix AB (publ) announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company's commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology. As a highly respected cardiologist expert, Dr. Talreja has been at the forefront of numerous groundbreaking research initiatives, pioneering advancements that have significantly impacted patient care and outcomes. He is a graduate of the University of Virginia School of Medicine, completed his Internship and Residency at Vanderbilt University Medical Center, and fellowship at the Mayo School of Medicine. Dr. Talreja is board certified by the American Board of Internal Medicine (ABIM) in cardiovascular disease, interventional cardiology, and internal medicine: He is currently the Medical Director of the Cardiovascular Service Line at Sentara Health. Dr. Talreja's vast experience and leadership experience in cardiac electrical system procedures, interventional cardiac procedures, heart conditions and overall cardiac patient care align very well with Acarix's mission to develop patient-focused innovative solutions that address some of the challenges in early cardiac healthcare.お知らせ • May 12Acarix AB Elects Mikael Thorén as DirectorAcarix AB elected Mikael Thorén as new director at the AGM held on May 11, 2023.お知らせ • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023お知らせ • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024お知らせ • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023収支内訳Acarix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ACIX.F 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 268-43361331 Dec 257-48391530 Sep 257-52411830 Jun 256-62432331 Mar 256-65462531 Dec 246-66472530 Sep 246-72512730 Jun 246-71522531 Mar 246-76532831 Dec 236-78542930 Sep 237-78533030 Jun 236-82563131 Mar 236-79542931 Dec 226-77532830 Sep 225-71512330 Jun 225-60432131 Mar 224-55392031 Dec 214-52332130 Sep 214-47302030 Jun 213-45301831 Mar 213-42291531 Dec 202-41291430 Sep 202-40271430 Jun 201-43251831 Mar 202-44262031 Dec 192-46282030 Sep 191-48292130 Jun 192-50331931 Mar 191-47321631 Dec 181-42311230 Sep 181-43321130 Jun 181-3730831 Mar 181-3428731 Dec 171-3026530 Sep 170-3230430 Jun 170-5531231 Mar 170-5028131 Dec 160-4826130 Sep 160-35113質の高い収益: ACIX.Fは現在利益が出ていません。利益率の向上: ACIX.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ACIX.Fは利益が出ておらず、過去 5 年間で損失は年間1.8%の割合で増加しています。成長の加速: ACIX.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ACIX.Fは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 14.8% ) と比較することは困難です。株主資本利益率高いROE: ACIX.Fは現在利益が出ていないため、自己資本利益率 ( -115.72% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 23:41終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Acarix AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関John SavinEdison Investment ResearchLudvig SvenssonRedeyeFilip EinarssonRedeye1 その他のアナリストを表示
お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027
お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024
お知らせ • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023
お知らせ • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024
お知らせ • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023
お知らせ • Feb 13Acarix AB (publ), Annual General Meeting, May 13, 2026Acarix AB (publ), Annual General Meeting, May 13, 2026.
お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027
お知らせ • Jun 26Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®? System in U.S. Emergency DepartmentsAcarix announced the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®? System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor®? system with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings-estimated between $7.3 million and $15.3 million per 10,000 patients-without compromising patient safety. The CADScor®? System are FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care.
お知らせ • May 14Acarix AB (Publ) Approves Election of Jan Poulsen as Director and Chair of the BoardAcarix AB (publ) announced that at its AGM held on 13 May 2025, the shareholders approved election of Jan Poulsen as new director. Jan Poulsen was elected as chair of the board.
お知らせ • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • Nov 12Acarix AB (publ), Annual General Meeting, May 15, 2025Acarix AB (publ), Annual General Meeting, May 15, 2025. Location: stockholm Sweden
お知らせ • Aug 13Acarix Expands Within US Wellness Exam MarketAcarix announced expanded use of the CADScor System within wellness exams as part of self-insured companies' health plans. As healthcare costs continue to rise, the CADScor System has now been proven to be an easy and quick strategy to risk stratify patients for significant coronary artery disease. The US employer self-insured market is rapidly expanding to include approximately 60 million Americans. In a self-funded insurance plan, companies bear the direct financial responsibility for their employee's healthcare costs and are acutely aware of the impact that serious health events, such as heart attacks, can have on their bottom line. Acarix has expanded its presence in the self-insured healthcare market, focusing on providing solutions for wellness exams. The first strategic account was signed with Delaware Resource Group, which successfully assessed its employees and families with the CADScor System.
お知らせ • Jul 05Acarix AB (publ) announced that it expects to receive SEK 21 million in fundingAcarix AB (publ) announced a private placement to issue 60,000,000 common shares at an issue price of SEK 0.35 per share for the gross proceeds of SEK 21,000,000 on July 3, 2024.
お知らせ • Jun 13Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation StudyAcarix announced the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.
お知らせ • May 29Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024Acarix AB (publ) announced appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix. Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik Inc., St. Jude Medical, Guidant Corp. (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes. Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships.
お知らせ • May 15Acarix AB (publ) Approves Board ElectionsAcarix AB (publ) at its AGM held on May 14, 2024 approved election of Ken Nelson and Dr. Tony Das as new directors.
お知らせ • Apr 11Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation StudyAcarix AB announced the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Second Quarter 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States.
お知らせ • Feb 15Acarix Appoints New Members to the Advisory BoardAcarix announced the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments. Ken Nelson brings over two decades of experience in the digital health, medical device, and remote patient monitoring industries. As a partner in the Medtech Advantage Fund and Chairman of the Board for CardiaCare, Mr. Nelson has played pivotal roles in numerous disruptive cardiac digital health and MedTech startups worldwide. His track record includes leadership positions in top market share players such as BioTelemetry, iRhythm, and Bardy Diagnostics. Dr. Saumil R. Oza, MD, is an electrophysiologist practicing in Jacksonville, FL, with over 15 years of experience and numerous publications. Renowned as a national expert in cardiology, Dr. Oza serves on advisory boards for established companies like Boston Scientific, Johnson and Johnson, GE, and Novo Nordisk, as well as biotech startups. His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market. Dave Braun, a strategic, customer-driven entrepreneur with over four decades of leadership experience, joins Acarix as an advisor. His extensive background in strategic business planning, mergers and acquisitions, banking and investor relations, organization development, and team building will bring a fresh perspective to operational strategies. Adding these three advisors emphasizes Acarix's commitment to driving innovation in cardiac health while expanding its reach in the United States. The new advisory board members will enhance efforts to develop solutions that improve patient outcomes and advance the standard of care in cardiac diagnostics.
お知らせ • Feb 02Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Security Name: Shares Security Type: Common Stock Securities Offered: 181,005,581 Price\Range: SEK 0.186
お知らせ • Feb 01Acarix AB (publ) Announces CEO ChangesThe Board of Acarix AB (publ) announced the appointment of Aamir Mahmood as new CEO with immediate effect, starting February 1, 2024. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024. Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO). Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. Aamir Mahmood assumed the CEO position on February 1, 2024.
お知らせ • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024
お知らせ • Nov 24Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare NetworkAcarix AB (publ) announced an advancement in the utilization of its CADScor System within the Veterans Administration (VA) Healthcare network. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system. The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test. In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System.
お知らせ • Oct 19Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 90,573,602 Price\Range: SEK 0.6 Transaction Features: Rights Offering
お知らせ • Aug 29Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical AdvisorAcarix AB (publ) announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company's commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology. As a highly respected cardiologist expert, Dr. Talreja has been at the forefront of numerous groundbreaking research initiatives, pioneering advancements that have significantly impacted patient care and outcomes. He is a graduate of the University of Virginia School of Medicine, completed his Internship and Residency at Vanderbilt University Medical Center, and fellowship at the Mayo School of Medicine. Dr. Talreja is board certified by the American Board of Internal Medicine (ABIM) in cardiovascular disease, interventional cardiology, and internal medicine: He is currently the Medical Director of the Cardiovascular Service Line at Sentara Health. Dr. Talreja's vast experience and leadership experience in cardiac electrical system procedures, interventional cardiac procedures, heart conditions and overall cardiac patient care align very well with Acarix's mission to develop patient-focused innovative solutions that address some of the challenges in early cardiac healthcare.
お知らせ • May 12Acarix AB Elects Mikael Thorén as DirectorAcarix AB elected Mikael Thorén as new director at the AGM held on May 11, 2023.
お知らせ • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023
お知らせ • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024
お知らせ • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023